Document is current
Any future updates will be listed below
-
Authors
Aberle, Jens
Menzen, Markus
Schmid, Sebastian M.
Terkamp, Christoph
Jaeckel, Elmar
Rohwedder, Katja
Scheerer, Markus F.
Xu, John
Tang, Weifeng
Birkenfeld, Andreas L.
-
Funding
Funding for this research was provided by:
AstraZeneca
Projekt DEAL
- License Information
-
More Information
Article History
Received: 18 August 2020
Accepted: 5 November 2020
First Online: 28 December 2020
Competing interests
: J.A. has received researching funding from AstraZeneca and honoraria for lecturing or consulting from AstraZeneca and Boehringer Ingelheim. M.M. received lecture fees from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, MSD and serves on advisory boards for AstraZeneca, Novo Nordisk, Eli Lilly. S.M.S. received lecture fees from AstraZeneca and Boehringer Ingelheim and served on advisory boards for AstraZeneca and Boehringer Ingelheim. C.T. received lecture fees from and served on advisory boards for AstraZeneca, Lilly, MSD and Novo Nordisk. E.J. has received honoraria for lecturing and consulting from AstraZeneca. K.R. is an employee of AstraZeneca. M.F.S. is a former employee of AstraZeneca and current employee of Bayer Pharmaceuticals. J.X. & W.T. are employees and shareholders of AstraZeneca. A.L.B. received lecture fees from AstraZeneca and Boehringer Ingelheim and served on advisory boards for AstraZeneca and Boehringer Ingelheim.
